Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Deepa Visavadia

Departmental Administrator

Deepa Visavadia

T: 020 3108 3280
E: d.visavadia@ucl.ac.uk

Deepa Visavadia is the Departmental Administrator for UCL Enterprise. Deepa's responsibilities include managing the finances, HR, administration and office management of UCL Enterprise.

Deepa joined UCL in 1994 where she worked at the Development Planning Unit for 10 years and later moved on to Department of Medicine before transferring to UCL Advances in February 2007. Before joining UCL, Deepa worked for the United Nations Centre for Human Settlements (Habitat) in Nairobi, Kenya.